3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Multiple Myeloma
58
Lymphoma, Large B-Cell, Diffuse
25
Lymphoma, Follicular
23
Lymphoma
18
Leukemia, Lymphocytic, Chronic, B-Cell
17
Recurrence
16
Lymphoma, Non-Hodgkin
14
Lymphoma, Mantle-Cell
14
Lymphoma, B-Cell, Marginal Zone
12
Lymphoma, B-Cell
10
Neoplasms, Plasma Cell
9
Waldenstrom Macroglobulinemia
6
Hodgkin Disease
6
Neoplasms
5
Leukemia, Myeloid, Acute
5
Burkitt Lymphoma
5
Lymphoma, T-Cell
4
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Large-Cell, Anaplastic
3
Leukemia
3
Hematologic Neoplasms
3
Sezary Syndrome
2
Paraproteinemias
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Mycosis Fungoides
2
Lymphoma, Large-Cell, Immunoblastic
2
Interventions
Temozolomide
14
Radiotherapy
14
Carboplatin
7
Irinotecan
6
Everolimus
5
Filgrastim
4
Carmustine
4
Surgical Procedures, Operative
3
Radiation
3
Paclitaxel
3
Ifosfamide
3
selpercatinib
2
pembrolizumab
2
Trastuzumab
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Methotrexate
2
Imatinib Mesylate
2
IL13-PE38
2
Dasatinib
2
Chemotherapy, Adjuvant
2
Bevacizumab
2
vitespin
1
veliparib
1
vatalanib
1
transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38)
1
tipifarnib
1
terameprocol
1
temsirolimus
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Central Nervous System Neoplasms
×
Lenalidomide
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled